Computational design of an ultrapotent deltacoronavirus miniprotein inhibitor
Proceedings of the National Academy of Sciences · 05.05.2026 · 123 (18)
DOI: 10.1073/pnas.2533456123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 29.04.2026. Verfasst von Nathan G Avery und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Washington, Seattle, WA 98195. Hauptthemen laut MEDLINE: Deltacoronavirus, Antiviral Agents. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHMI (HHMI).
Abstract (Originalsprache)
Multiple spillovers of porcine deltacoronavirus (PDCoV) into humans in Haiti highlight its zoonotic potential and the need for targeted interventions. No approved vaccines or therapeutics are available for use in humans against any DCoVs. Here, we report the de novo design of PDCoV miniprotein inhibitors (aka minibinders, MBs) and show that one of them, MB11, binds with picomolar affinity to the PDCoV receptor-binding domain (RBD). MB11 potently inhibits PDCoV, outcompeting monoclonal antibodies, and cross-reacts with and broadly neutralizes a panel of distantly related DCoVs. We determined a cryoelectron microscopy structure of MB11 bound to the PDCoV RBD which reveals the molecular basis of broad DCoV neutralization through interference with host receptor engagement. Deep mutational scanning of the PDCoV RBD reveals that MB11 has a high barrier to viral escape with only few mutations mediating escape without dampening APN receptor binding. MB11 resists stringent biochemical stresses, including high temperature, low pH, and proteolysis, which may enable delivery to various tissues for viral inhibition. This work delineates a prime candidate for clinical evaluation against PDCoV infection and for pandemic preparedness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, University of Washington, Seattle, WA 98195.
- Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT 84112.
- HHMI, University of Washington, Seattle, WA 98195.
- Humabs Biomed SA, a Subsidiary of Vir. Biotechnology, Bellinzona 6500, Switzerland.
ORCID-Profile: Nathan G Avery, Young-Jun Park, Davide Corti, Fabio Benigni, Tyler N Starr, David Veesler
Förderung
- NIAID NIH HHS
- HHMI (HHMI)
Zitieren
APA
Avery, N. G., Yoshiyama, C. N., Taylor, A. L., Park, Y. J., Asarnow, D., Perruzza, L., Brown, J. T., Corti, D., Benigni, F., Starr, T. N., & Veesler, D. (2026). Computational design of an ultrapotent deltacoronavirus miniprotein inhibitor. Proceedings of the National Academy of Sciences, 123(18). https://doi.org/10.1073/pnas.2533456123
Vancouver
Avery NG, Yoshiyama CN, Taylor AL, Park YJ, Asarnow D, Perruzza L, et al. Computational design of an ultrapotent deltacoronavirus miniprotein inhibitor. Proceedings of the National Academy of Sciences. 2026;123(18). doi:10.1073/pnas.2533456123
BibTeX
@article{Avery2026,
author = {Avery, Nathan G and Yoshiyama, Courtney N and Taylor, Ashley L and Park, Young-Jun and Asarnow, Daniel and Perruzza, Lisa and Brown, Jack T and Corti, Davide and Benigni, Fabio and Starr, Tyler N and Veesler, David},
title = {Computational design of an ultrapotent deltacoronavirus miniprotein inhibitor},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {18},
doi = {10.1073/pnas.2533456123}
}
EUVIMED